Can you take Medex-LA with Tirzepatide?

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Benign Prostatic Hyperplasia.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

The phenylpropanolamine in Medex-LA has a major potential interaction with Cardiovascular Conditions and Disorders.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylpropanolamine in Medex-LA has a major potential interaction with Cerebrovascular Insufficiency.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Tirzepatide has a moderate potential interaction with Dehydration.

Tirzepatide has been associated with gastrointestinal adverse reactions (including nausea, vomiting, diarrhea); such events may lead to dehydration, which could cause acute kidney injury if severe. There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure (which may sometimes require hemodialysis) in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists; some of these events were reported in patients without known underlying renal disease, and most of the reported cases occurred in patients who experienced nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored when starting or escalating doses of tirzepatide in patients with renal dysfunction reporting severe gastrointestinal adverse reactions. No dose adjustment is recommended for patients with renal dysfunction.

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Diabetes Mellitus.

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

Tirzepatide has a moderate potential interaction with Diabetic Retinopathy.

Tirzepatide has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema; caution is recommended in these patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Tirzepatide has a moderate potential interaction with Diarrhea.

Tirzepatide has been associated with gastrointestinal adverse reactions (including nausea, vomiting, diarrhea); such events may lead to dehydration, which could cause acute kidney injury if severe. There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure (which may sometimes require hemodialysis) in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists; some of these events were reported in patients without known underlying renal disease, and most of the reported cases occurred in patients who experienced nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored when starting or escalating doses of tirzepatide in patients with renal dysfunction reporting severe gastrointestinal adverse reactions. No dose adjustment is recommended for patients with renal dysfunction.

Tirzepatide has a moderate potential interaction with Gastroparesis.

Use of tirzepatide has been associated with gastrointestinal adverse reactions (sometimes severe). Because tirzepatide has not been studied in patients with severe gastrointestinal disease (including severe gastroparesis), it is not recommended in these patients.

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.

The phenylpropanolamine in Medex-LA has a major potential interaction with Hyperthyroidism.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Tirzepatide has a major potential interaction with Multiple Endocrine Neoplasia Type II.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of tirzepatide and should be informed of symptoms of thyroid tumors.

Tirzepatide has a moderate potential interaction with Pancreatitis.

Acute pancreatitis (including fatal and nonfatal hemorrhagic or necrotizing pancreatitis) has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists; acute pancreatitis has been reported in patients treated with tirzepatide in clinical trials. Tirzepatide has not been studied in patients with history of pancreatitis; it is unknown if such patients are at higher risk of developing pancreatitis on tirzepatide. After initiation of tirzepatide, patients should be observed carefully for signs/symptoms of pancreatitis (including persistent severe abdominal pain [sometimes radiating to the back], with or without vomiting); if pancreatitis is suspected, tirzepatide should be discontinued and appropriate management should be started.

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Prostate Tumor, Benign.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Psychiatric Disorders.

Phenylpropanolamine may precipitate or exacerbate psychotic symptoms, particularly at high dosages. Therapy with phenylpropanolamine should be administered cautiously in patients with a history of psychiatric disorders.

The phenylpropanolamine in Medex-LA has a moderate potential interaction with Psychosis.

Phenylpropanolamine may precipitate or exacerbate psychotic symptoms, particularly at high dosages. Therapy with phenylpropanolamine should be administered cautiously in patients with a history of psychiatric disorders.

Tirzepatide has a moderate potential interaction with Renal Dysfunction.

Tirzepatide has been associated with gastrointestinal adverse reactions (including nausea, vomiting, diarrhea); such events may lead to dehydration, which could cause acute kidney injury if severe. There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure (which may sometimes require hemodialysis) in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists; some of these events were reported in patients without known underlying renal disease, and most of the reported cases occurred in patients who experienced nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored when starting or escalating doses of tirzepatide in patients with renal dysfunction reporting severe gastrointestinal adverse reactions. No dose adjustment is recommended for patients with renal dysfunction.

Tirzepatide has a major potential interaction with Thyroid Tumor.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of tirzepatide and should be informed of symptoms of thyroid tumors.

Tirzepatide has a moderate potential interaction with Vomiting.

Tirzepatide has been associated with gastrointestinal adverse reactions (including nausea, vomiting, diarrhea); such events may lead to dehydration, which could cause acute kidney injury if severe. There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure (which may sometimes require hemodialysis) in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists; some of these events were reported in patients without known underlying renal disease, and most of the reported cases occurred in patients who experienced nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored when starting or escalating doses of tirzepatide in patients with renal dysfunction reporting severe gastrointestinal adverse reactions. No dose adjustment is recommended for patients with renal dysfunction.